Assembly Biosciences Inc (ASMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$36.60+1.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ASMB
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $37 ASMB trades at 36× p/e — 1.6× the 22× p/e peer median. The market is re-rating it beyond its own range; our $38 fair value is medium-confidence here. Analysts target $45–$53. Note: our $38 fair value sits below the entire analyst range ($45–$53). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $51.00 | — | — | Analyst | high |
| Peer P/E | 12M | $22.43 | 22.0 | 1.02 | TTM | high |
| Peer P/S | 12M | $25.36 | 11.4 | 2.23 | TTM | high |
| triangulated | 12M | $24.06 | 22.0 | 1.09 | Triangulated | high |
| Peer P/S | 3Y |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
$45.00 – $53.00 (median $51.00) · 4 analysts · as of 2026-09-01
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
| $26.78 |
| 11.4 |
| 2.35 |
| Analyst |
| medium |
| Peer P/S | 5Y | $27.75 | 11.4 | 2.44 | Analyst | medium |